Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

[1] Tryfonidis K(2015)Management of locally advanced breast cancer-perspectives and future directions Nat Rev Clin Oncol 12 147-162

[2] Senkus E(2011)Treatment of metastatic breast cancer: second line and beyond Ann Oncol 22 1000-1010

[3] Cardoso MJ(2012)Eribulin mesylate in the treatment of metastatic breast cancer Biologics. 6 21-29

[4] Cardoso F(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 777-784

[5] Roche H(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 e1000100-900

[6] Vahdat LT(2005)Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ. 331 897-3124

[7] Jain S(2004)Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 3105-601

[8] Cigler T(2015)Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 33 594-84

[9] Hutton B(2016)Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer Breast Cancer (Auckl) 10 77-520

[10] Salanti G(2015)Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Breast Cancer Res Treat 154 509-374

[1] Tryfonidis K(2015)Management of locally advanced breast cancer-perspectives and future directions Nat Rev Clin Oncol 12 147-162

[2] Senkus E(2011)Treatment of metastatic breast cancer: second line and beyond Ann Oncol 22 1000-1010

[3] Cardoso MJ(2012)Eribulin mesylate in the treatment of metastatic breast cancer Biologics. 6 21-29

[4] Cardoso F(2015)The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations Ann Intern Med 162 777-784

[5] Roche H(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration PLoS Med 6 e1000100-900

[6] Vahdat LT(2005)Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ. 331 897-3124

[7] Jain S(2004)Combination of direct and indirect evidence in mixed treatment comparisons Stat Med 23 3105-601

[8] Cigler T(2015)Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 33 594-84

[9] Hutton B(2016)Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer Breast Cancer (Auckl) 10 77-520

[10] Salanti G(2015)Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial Breast Cancer Res Treat 154 509-374